Durect dives on Posidur rejection

Shares of Durect plummeted 30% in after-hours trading on 12 February after the company revealed it had received a complete response letter (CRL) from the FDA for the drug maker’s post-operative pain relief product Posidur, which uses the firm’s Saber technology to deliver bupivacaine.